Diurnal Group: And then there were three

Diurnal Group plc (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its products are targeting rare conditions where medical need is currently unmet, with the long-term aim of building an “Adrenal Franchise”. Alkindi® was approved by the European regulators in September 2018, and has been launched in 10 countries. Now it has been approved for the US market, with Diurnal receiving formal approval from the FDA. This is an important value-inflection milestone that only two other AIM-listed companies have reached. Marketing partner, Eton Pharmaceuticals (Eton), has high US sales expectations.

  • Strategy: Diurnal’s goal is to create a valuable “Adrenal Franchise” that can treat patients with chronic cortisol deficiency diseases from birth and for the rest of their lives. The long-term vision, once Alkindi and Chronocort are established in Europe and the US, is to expand the product offering to other endocrine conditions.
  • Alkindi: Alkindi, or Alkindi Sprinkle, as it will be known in the US, is an immediate-release hydrocortisone preparation for the control of adrenal insufficiency (AI), including congenital adrenal hyperplasia (CAH), in children aged up to 18 years of age. It is currently being sold in 10 countries across Europe.
  • FDA approval: Diurnal submitted a New Drug Application (NDA) with the US Food and Drug Administration (FDA) for Alkindi Sprinkle in November 2019, which was accepted for review in February 2020. The FDA formally approved the drug for commercialisation on its PDUFA date, 29 September 2020.
  • Commercialisation: FDA approval has de-risked the drug. Diurnal signed an exclusive US licensing deal for the commercialisation of Alkindi Sprinkle with Eton on 27 March 2020. Sales should start in early 2021, at which point a $2.5m milestone will be triggered. Eton is forecasting peak sales in excess of $100m.
  • Investment summary: Diurnal Group has become only the third listed AIM company to obtain FDA approval for a drug. Since signing the commercial deal, Eton has been readying itself to add Alkindi into its existing supply chain and commercial infrastructure, so that first sales can occur shortly after approval. Diurnal has other significant value-inflection points in the next six months. Meanwhile, the shares are trading well below our updated risk-adjusted DCF valuation (223p).

DOWNLOAD THE FULL REPORT

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Hardman & Co

    More articles like this

    Hardman & Co

    Diurnal Group: All set for three pivotal trials

    Diurnal Group plc (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its drugs target conditions where medical need is currently unmet, with the aim of becoming a global endocrine leader.

    Hardman & Co

    Diurnal Group: Closely watching the regulators

    Diurnal Group plc (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its products are targeting rare conditions where medical need is currently unmet, with the long-term aim of building an

    Hardman & Co

    Diurnal Group Flow of regulatory approvals

    Diurnal Group plc (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its products are targeting rare conditions where medical need is currently unmet, with the long-term aim of building an

    Hardman & Co

    Diurnal Group … and more to come (news flow)

    Diurnal Group PLC (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products are targeting rare conditions where medical need is currently unmet, with the aim of building

    Hardman & Co

    Diurnal Group Plc Successful DITEST Phase I trial outcome

    Diurnal (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products, Alkindi and Chronocort, are in late-stage clinical trials, with Alkindi already licensed in Europe. With the successful

    Hardman & Co

    Diurnal Group Approaching a number of near-term milestones

    Diurnal (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products are targeting rare conditions where medical need is currently unmet, with the aim of building a long-term

    Hardman & Co

    Diurnal Group Plc Clarity for Chronocort regulatory pathway

    Diurnal Group Plc (LON: DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products are targeting rare conditions where medical need is currently unmet, with the aim of

    Hardman & Co

    Diurnal Group Chronocort – seeking regulatory advice

    Diurnal Group (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products target rare conditions where medical needs are currently unmet, with the aim of building a long-term

    Hardman & Co

    Diurnal Group Unexpected Phase III trial outcome

    Diurnal Group (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products target rare conditions where medical needs are currently unmet, with the aim of building a long-term

    Hardman & Co

    Diurnal Group Alkindi®: On route to Europe

    Diurnal Group Plc (LON:DNL) is a clinical stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead candidates are targeted at rare diseases with unmet medical need, with the aim of building

    Hardman & Co

    Diurnal Group Plc Ready to press the button

    Diurnal Group Plc (LON:DNL) is a clinical stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead candidates are targeted at rare diseases with unmet medical need, with the aim of building